399 related articles for article (PubMed ID: 20631300)
1. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
Anguille S; Van de Velde AL; Smits EL; Van Tendeloo VF; Juliusson G; Cools N; Nijs G; Stein B; Lion E; Van Driessche A; Vandenbosch I; Verlinden A; Gadisseur AP; Schroyens WA; Muylle L; Vermeulen K; Maes MB; Deiteren K; Malfait R; Gostick E; Lammens M; Couttenye MM; Jorens P; Goossens H; Price DA; Ladell K; Oka Y; Fujiki F; Oji Y; Sugiyama H; Berneman ZN
Blood; 2017 Oct; 130(15):1713-1721. PubMed ID: 28830889
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
5. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
[TBL] [Abstract][Full Text] [Related]
6. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
7. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
[TBL] [Abstract][Full Text] [Related]
9. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the WT1
Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
12. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
13. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
[TBL] [Abstract][Full Text] [Related]
14. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
[TBL] [Abstract][Full Text] [Related]
15. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
[TBL] [Abstract][Full Text] [Related]
17. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
19. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
Kuball J; de Boer K; Wagner E; Wattad M; Antunes E; Weeratna RD; Vicari AP; Lotz C; van Dorp S; Hol S; Greenberg PD; Heit W; Davis HL; Theobald M
Cancer Immunol Immunother; 2011 Feb; 60(2):161-71. PubMed ID: 20963411
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Maslak PG; Dao T; Bernal Y; Chanel SM; Zhang R; Frattini M; Rosenblat T; Jurcic JG; Brentjens RJ; Arcila ME; Rampal R; Park JH; Douer D; Katz L; Sarlis N; Tallman MS; Scheinberg DA
Blood Adv; 2018 Feb; 2(3):224-234. PubMed ID: 29386195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
